MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today reported financial results for the quarter ended June 30, 2007. Depomed reported a net loss of $9.0 million, or 20 cents per share, for the second quarter of 2007 compared to a net loss of $9.9 million or 24 cents per share for the second quarter of 2006. Cash, cash equivalents and marketable securities at quarter end were $35.4 million, which excludes an additional $17.5 million payment received in July 2007 pursuant to its previously disclosed termination agreement with Esprit Pharma.
